Corilagin |
Catalog No.GN10346
One-Click Copy Product Info
|
Corilagin, a natural plant polyphenol tannic acid, is a potent inhibitor of the binding of SARS CoV-2 spike protein RBD to host receptor angiotensin-converting enzyme 2 (ACE2), with an IC50 value of 5.5μM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 23094-69-1
Sample solution is provided at 25 µL, 10mM.
Corilagin, a natural plant polyphenol tannic acid, is a potent inhibitor of the binding of SARS CoV-2 spike protein RBD to host receptor angiotensin-converting enzyme 2 (ACE2), with an IC50 value of 5.5μM[1]. Corilagin, as a non-nucleoside inhibitor of SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), directly binds to RdRp and effectively inhibits the SARS-CoV-2 replication, with an EC50 value of 0.13μM[2]. Corilagin possesses potential anti-inflammatory and anti-virus properties, and has been widely applied in various anti-cancer researches[3].
In vitro, Corilagin inhibited the viability of ovarian cancer cells and the IC50 values for 24 hours and 48 hours of treatment with Corilagin on A2780 cells were 61.32μM and 47.81μM, respectively[4]. Treatment of MCF-7 cells with 80μM Corilagin for 48 hours significantly inhibited cell growth and activated both intrinsic and extrinsic mitochondrial apoptotic pathways[5]. Corilagin treatment (40μM; 48h) induced cell cycle arrest in cholangiocarcinoma cells, suppressed cell proliferation and inhibited the expression of Notch1 protein[6].
In vivo, Corilagin treatment via intragastric administration (40mg/kg/day) for one month significantly reduced the levels of inflammatory factors in the plasma of rats with peripheral artery disease (PAD) model, and alleviated the severity of atherosclerotic lesions in the arteries[7]. In the rabbit atherosclerosis model induced by high-fat diet (HFD), after 4 weeks of intragastric administration with 4mg/kg/day dose of Corilagin, the levels of serum total cholesterol, triglyceride and low-density lipoprotein cholesterol were significantly reduced, the level of high-density lipoprotein cholesterol was increased, the intimal thickening of the thoracic aorta was reduced, and the formation of foam cells was decreased[8]. Intraperitoneal injection with 30mg/kg/day of Corilagin for one week disrupted the nuclear receptor coactivator 4 (NCOA4)-ferritin interaction and inhibited ferroptosis mediated by ferroprotein phagocytosis, thereby alleviating intestinal ischemia/reperfusion injury in mice[9].
References:
[1] Hanson Q M, Wilson K M, Shen M, et al. Targeting ACE2–RBD interaction as a platform for COVID-19 therapeutics: development and drug-repurposing screen of an AlphaLISA proximity assay[J]. ACS Pharmacology & Translational Science, 2020, 3(6): 1352-1360.
[2] Li Q, Yi D, Lei X, et al. Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase[J]. Acta Pharmaceutica Sinica B, 2021, 11(6): 1555-1567.
[3] Li X, Deng Y, Zheng Z, et al. Corilagin, a promising medicinal herbal agent[J]. Biomedicine & Pharmacotherapy, 2018, 99: 43-50.
[4] Xu Z, Jiang Y, Shan T, et al. Study on the Effects and Mechanism of Corilagin on A2780 Cell Apoptosis[J]. Current Issues in Molecular Biology, 2025, 47(2): 105.
[5] Tong Y, Zhang G, Li Y, et al. Corilagin inhibits breast cancer growth via reactive oxygen species‐dependent apoptosis and autophagy[J]. Journal of cellular and molecular medicine, 2018, 22(8): 3795-3807.
[6] Gu Y, Xiao L, Ming Y, et al. Corilagin suppresses cholangiocarcinoma progression through Notch signaling pathway in vitro and in vivo[J]. International Journal of Oncology, 2016, 48(5): 1868-1876.
[7] Li Y, Wang Y, Chen Y, et al. Corilagin ameliorates atherosclerosis in peripheral artery disease via the toll-like receptor-4 signaling pathway in vitro and in vivo[J]. Frontiers in immunology, 2020, 11: 1611.
[8] He B, Chen D, Zhang X, et al. Antiatherosclerotic effects of corilagin via suppression of the LOX-1/MyD88/NF-κB signaling pathway in vivo and in vitro[J]. Journal of Natural Medicines, 2022, 76(2): 389-401.
[9] Wang Y, Li B, Liu G, et al. Corilagin attenuates intestinal ischemia/reperfusion injury in mice by inhibiting ferritinophagy-mediated ferroptosis through disrupting NCOA4-ferritin interaction[J]. Life sciences, 2023, 334: 122176.
| Cell experiment [1]: | |
Cell lines | MCF-7 cells |
Preparation Method | The MCF-7 cells were cultured in DMEM medium supplemented with 10% fetal bovine serum and 100U/mL penicillin/streptomycin, under a 5% CO2 and 95% air environment at 37℃. The cells were seeded at a density of 5 × 103 cells per well in a 96-well plate, then treated with Corilagin (0, 20, 40, 60, 80, 100μM) for 48 hours, followed by the addition of 20μL MTT (5mg/mL) for 4 hours, and finally 150μL DMSO was added. The absorbance was measured at 490nm using an enzyme reader. The cell proliferation status was detected using the EdU cell proliferation detection kit, and the number of cells incorporating EdU was determined by fluorescence microscopy. |
Reaction Conditions | 0, 20, 40, 60, 80, 100μM; 48h |
Applications | Corilagin significantly inhibited MCF-7 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Athymic nude mice |
Preparation Method | 200µL of 1 × 107 Hep-2 cells were injected subcutaneously into the right side of each 4-5-week-old athymic nude mouse to establish a laryngeal cancer transplantation model. When the tumor volume reached 100mm3, the tumor-bearing mice were randomly divided into 3 groups, with 5 mice in each group. All mice were intraperitoneally injected with 30mg/kg Corilagin once every 3 days. The tumor volume was measured every 4 days for a total of 28 days. The length and width of the subcutaneous transplanted tumors were measured using a vernier caliper. The formula for calculating tumor volume (V) is: V = 0.5×width2×length. After treatment (28 days), the mice were anesthetized with isoflurane and euthanized, the xenograft tumor samples of the nude mice were embedded in paraffin, rinsed with cold saline, and cut into 5µm sections. Then, the samples were fixed in 10% formaldehyde neutral buffer solution and stained with hematoxylin-eosin. |
Dosage form | 30mg/kg, once every 3 days for 28 days; i.p. |
Applications | Corilagin treatment inhibited growth of transplanted tumors and resulted in tumor chromatin condensation and structure loosening in the xenograft tumor mouse models. |
References: | |
| Cas No. | 23094-69-1 | SDF | |
| Canonical SMILES | C1C2C(C(C(C(O2)OC(=O)C3=CC(=C(C(=C3)O)O)O)O)OC(=O)C4=CC(=C(C(=C4C5=C(C(=C(C=C5C(=O)O1)O)O)O)O)O)O)O | ||
| Formula | C27H22O18 | M.Wt | 634.45 |
| Solubility | DMF: 20 mg/ml,DMSO: 25 mg/ml,Ethanol: 25 mg/ml,PBS (pH 7.2): 5 mg/ml | Storage | Store at 2-8°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.5762 mL | 7.8808 mL | 15.7617 mL |
| 5 mM | 315.2 μL | 1.5762 mL | 3.1523 mL |
| 10 mM | 157.6 μL | 788.1 μL | 1.5762 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)